No evidence that amifostine influences the plasma pharmacokinetics of topotecan in ovarian cancer patients

Autor: Carsten Peterson, Henric Malmström, Anna-Lena Zackrisson

Publikováno v: European Journal of Clinical Pharmacology. 58:103-108

This aim of this study was to compare the pharmacokinetics of topotecan in the presence and absence of preceding amifostine to reduce the risk of side effects in patients with advanced ovarian cancer.Ten patients with advanced ovarian cancer received

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6cd4eb8137466868c2326a02bfa50ceb
https://doi.org/10.1007/s00228-002-0434-9

Endometrial stromal sarcoma of the uterus: a clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 17 cases

Autor: Claudio Guerrieri, Henric Malmström, René Blom

Publikováno v: International Journal of Gynecological Cancer. 9:98-104

Seventeen patients with endometrial stromal sarcoma (ESS) diagnosed between 1970 and 1996 were evaluated according to DNA ploidy, S-phase fraction (SPF), p53, and mdm-2 expression, as well as traditional clinical and pathologic prognostic factors, su

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::692a0942e353055758ae0e64284ebe7c
https://doi.org/10.1046/j.1525-1438.1999.09870.x

Leiomyosarcoma of the Uterus: A Clinicopathologic, DNA Flow Cytometric, p53, and mdm-2 Analysis of 49 Cases

Autor: René Blom, Ernst Simonsen, Olle Stål, Henric Malmström, Claudio Guerrieri

Publikováno v: Gynecologic Oncology. 68:54-61

The authors analyzed in a retrospective manner the prognostic significance of p53 and mdm-2 expression, DNA ploidy, S-phase fraction (SPF), and traditional clinical and pathological prognostic factors in patients with uterine leiomyosarcomas.Forty-ni

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7579de23323c9dba28ce00541fbb9b35
https://doi.org/10.1006/gyno.1997.4889

Granulosa Cell Tumors of the Ovary: Prognostic Factors and Outcome

Autor: Thomas Högberg, Henric Malmström, Björn Risberg, Ernst Simonsen

Publikováno v: Gynecologic Oncology. 52:50-55

Granulosa and theca cell tumors of the ovary account for 2-3% of ovarian malignancies. This study includes 54 patients with the diagnosis of granulosa cell tumors of the ovary treated between 1953 and 1987. Median age at diagnosis was 57 (27-83) year

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9182043f9d58d211b16cb0dd896c391f
https://doi.org/10.1006/gyno.1994.1010

Phase II study of vinorelbine in the treatment of platinum-resistant ovarian carcinoma

Autor: Morten Høyer, Henric Malmström, Hanne Havsteen, Anders Jakobsen, Kamma Bertelsen, Peter Sørensen

Publikováno v: Sørensen, P, Høyer, M, Jakobsen, A, Malmström, H, Havsteen, H & Bertelsen, K 2001, ' Phase II study of vinorelbine in the treatment of platinum-resistant ovarian carcinoma ', Gynecologic Oncology, vol. 81, no. 1, pp. 58-62 . https://doi.org/10.1006/gyno.2000.6089
Sørensen, P, Høyer, M, Jakobsen, A, Malmström, H, Havsteen, H & Bertelsen, K 2001, ' Phase II Study of Vinorelbine in the Treatment of Platinum-Resistant Ovarian Carcinoma ', Gynecologic Oncology, vol. 81, pp. 58-62 .

Objective. The purpose of this phase II study was to evaluate on an intent-to-treat basis the activity and toxicity of single-agent vinorelbine (VRL) as second-line chemotherapy of patients with platinum-resistant ovarian cancer. Platinum-resistant d

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ff1b0b7b59ca64b124b82cd37f68322
https://pure.au.dk/portal/da/publications/phase-ii-study-of-vinorelbine-in-the-treatment-of-platinumresistant-ovarian-carcinoma(254583d0-9561-11da-bee9-02004c4f4f50).html